NASH Fibrosis Cirrhosis - Houston TX

Summary:

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF SIRNA GENE SILENCING FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN PARTICIPANTS WITH GENETIC RISK FACTORS

INCLUSION

-        Males or females females aged between 18 and 75 years

-        A diagnosis of NASH with fibrosis (F) stage 2 or 3

o High cholesterolExclusion criteria:

-        NO Chronic liver diseases other than NASH

-        NO eGFR < 45

-        NO alcohol/substance abuse within the last year

-        NO HbA1c ≥9.5%

-        NO Type 1 diabetes

-        NO bariatric surgery within last 5 years

-        NO Prior exposure to any investigational drug targeting HSD17B13 or PNPLA3 (eg, ALN-HSD or ARO-HSD, AZD2693).

Qualified Participants May Receive:

Stipend - $100